Home / Market News / $DXCM
fiscal.ai Corporate Catalyst Impact 85/100 ● positive

DexCom Reports Q3 2026 Financial Results and Raises Revenue Guidance

Oct 29, 2026, 10:11 PM UTC · Primary ticker $DXCM

DexCom reported strong Q3 2026 financial results, exceeding both revenue and EPS analyst estimates. The company subsequently raised its full-year 2026 revenue guidance, indicating robust performance in its continuous glucose monitoring business, which is likely to be viewed positively by investors.

DexCom announced Q3 2026 revenue of $1.34 billion, surpassing the FactSet consensus of $1.33 billion, and adjusted EPS of $0.73, beating estimates of $0.67. This strong performance led the company to raise its full-year 2026 revenue guidance to $5.20 billion-$5.25 billion. This is a significant positive catalyst for DexCom, as it demonstrates continued growth and market penetration in its core continuous glucose monitoring business. Investors will likely react positively to both the beat and the improved outlook, suggesting potential short-term upside for DXCM stock. The long-term implication is a reinforced positive sentiment for the company's growth trajectory in the diabetes management sector, though competitive pressures remain a key risk.

$DXCM positive Strong earnings beat and raised guidance
Source: fiscal.ai
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.